Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Abstract Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the efficacy and safety of regorafenib for patients with adv...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Toshihiko Matsumoto, Tatsuki Ikoma, Shogo Yamamura, Kou Miura, Takao Tsuduki, Takanori Watanabe, Hiroki Nagai, Masahiro Takatani, Hisateru Yasui
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Nature Portfolio 2023-02-01
Edice:	Scientific Reports
On-line přístup:	https://doi.org/10.1038/s41598-023-29706-6
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!